J&J said it could no longer provide sales forecasts for its Covid jab, after vaccine hesitancy in low-income countries and low demand in higher-income nations led to a glut of supply. The company had predicted as much as $3.5bn of vaccine sales in 2022.
US healthcare giant Johnson & Johnson suspends Covid vaccine sales forecast amid low demand
Share
